Navigation Links
Researchers Identify 2 Genes Linked to Fatty Liver Disease
Date:3/24/2010

Could yield better tests, treatments for condition that can cause liver damage, type 2 diabetes

WEDNESDAY, March 24 (HealthDay News) -- Researchers have identified two gene variants that increase the risk of both the most common chronic liver disease in the United States as well as type 2 diabetes.

People who carry the variants of a gene for apolipoprotein C3 (APOC3), which produces an enzyme important in fat metabolism, have a higher incidence of nonalcoholic fatty liver disease and also insulin resistance, according to a report in the March 25 issue of the New England Journal of Medicine. The research group was led by Dr. Gerald I. Shulman, a professor of physiological chemistry, medicine and cellular and molecular physiology at Yale University.

Identification of the gene variants "might make it possible to screen individuals to see if they have a higher risk of fatty liver disease," Shulman said. "It also can provide an ideal drug target to prevent development of fatty liver disease and insulin resistance."

Fatty liver disease can be caused by excessive alcoholic consumption and obesity. Its incidence has increased in the United States, and more than 30 percent of Americans are estimated to have it, Shulman said.

In many cases, excess buildup of fat in the liver causes only minor problems. But it can progress to cause major, life-threatening deterioration of liver function. In the same way, insulin resistance can lead to type 2 diabetes, a major risk factor for heart attack, stroke and other cardiovascular problems.

Shulman and his colleagues first looked for the APOC3 gene variants in 95 lean Asian Indian men, an ethnic group in which the incidence of fatty liver disease is high, for unknown reasons. "Carriers of these gene variants had 5.5 percent fat in their liver, and were also markedly insulin-resistant," Shulman said.

The variants cause higher levels of APO3C, which inhibits an enzyme that breaks down fats, Shulman said. The excess fats are deposited in the liver. Thirty-eight percent of the men with the gene variants had fatty liver disease.

The Yale group then did the same genetic study in a mixed ethnic group of 163 men and found a similar incidence of fatty liver disease and insulin resistance among those with the gene variants.

The next step in the Yale program will be an effort to learn why the condition is more common in East Asian men, Shulman said. But a longer-term goal is to put the finding to use to detect high-risk individuals, he noted.

"If you have a test, you can make them careful about their weight," he said. "The good news is that we have shown that even modest weight reduction can reduce the risk. Dropping 15 pounds reverses fatty liver disease and insulin resistance."

Beyond that would be a treatment aimed at the gene variants, Shulman said. "It's even better if you have something you can do about it," he said. "You could screen people, test for fatty liver and insulin resistance and treat that with agents."

A screening test could help single out people whose fatty livers were not dangerous, said Dr. Anna Mae Diehl, chief of gastroenterology at Duke University, who wrote an accompanying editorial in the journal.

"Simply having extra fat in the liver is of unknown significance," Diehl said. "Many people who have it are fine. Some get more advanced forms of liver disease. We want to know if this polymorphism is associated not only with fat, but also with damage."

Such a determination now requires a biopsy to remove a segment of the liver for examination, Diehl said. "We still don't have a noninvasive blood test," she said. "That might help sort out who has more serious damage. We are hoping that in the next few years better tests become available."

More information

To learn more about fatty liver disease, visit the American Liver Foundation.



SOURCES: Gerald I. Shulman, M.D., Ph.D, professor, physiological chemistry, medicine, cellular and molecular physiology, Yale University, New Haven, Conn.; Anna Mae Diehl, M.D., professor, medicine, and chief, gastroenterology, Duke University, Durham, N.C.; March 25, 2010, New England Journal of Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. NIA researchers find gene to explain mouse embryonic stem cell immortality
2. Researchers discover fundamental step in immune-system development
3. Scott & White Healthcare researchers studying investigational agent that targets breast cancer
4. SRI International Researchers to Present Work on Early Detection Tool for Neglected Tropical Diseases at 2010 American Chemical Society (ACS) Meeting
5. Researchers find new chemotherapy combination shows promise in endometrial cancer
6. Researchers ID brain abnormalities in children exposed to methamphetamine in utero
7. Mount Sinai researchers are the first to identify heart abnormalities in World Trade Center workers
8. Researchers discover chemical that may protect hearts of muscular dystrophy patients
9. Researchers recommend curriculum on unhealthy substance use
10. Using new approach, Mayo Clinic researchers find level of gene alters risk of Alzheimers disease
11. Researchers discover brain tumors grow-or-go switch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... An April 24th article on Yahoo! Beauty discusses ... with the help of a weight loss surgery. The woman, declaring “I will not hate ... been left following her dramatic weight loss. Dr. Feiz & Associates notes that, while it ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... its new partnership with the Home Care Association of America (HCAOA). This agreement ... Private Duty Accreditation services, as well as discounts on Accreditation University (AU) educational ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... to announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to ... since it streamlines the reporting process and provides a familiar interface that does ...
(Date:4/28/2017)... ... ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced today that ... as “stable.” At the same time, the ratings agency cautioned that the company’s rating ... “capital adequacy” thresholds required for its strong rating. , “Horizon is committed to being ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, Inc. announced today ... throughout the Northeast U.S. , GlycoMark is the only clinically available blood ... provides a clinically proven one- to two-week measure of hyperglycemic excursions, often related ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  Cogentix Medical, Inc. (NASDAQ: ... providing the Urology, Uro/Gyn and Gynecology markets with ... Keswani has joined the Company as Senior Vice ... created position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has ...
(Date:4/20/2017)...  RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage ... unmet medical needs, today announced that it will ... development program, based on its proprietary self-delivering RNAi ... (SID) 76 th Annual Meeting.  The SID ... relevant to skin health and disease through education, ...
(Date:4/20/2017)... April 20, 2017  AbbVie (NYSE: ABBV), a ... (n=145/146) of chronic hepatitis C virus (HCV) infected ... 6 and compensated cirrhosis (Child-Pugh A) achieved sustained ... ) with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir ... seen following 12 weeks of G/P treatment without ...
Breaking Medicine Technology: